Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (1000)	1/10/2002 1:32:31 PM
From: tuck	Respond to of 1784

DPII's recent advance related to to delayed reaction to PFE collaboration, munchworthiness, and now a milestone and fresh aggreement with Xenon: >>New York, New York, Jan 07, 2002 (Market News Publishing via COMTEX) -- Xenon Genetics Inc. announced that it has signed a second drug discovery agreement with Discovery Partners International Inc. (Nasdaq: DPII chart, msgs) to identify small molecule compounds active against a novel metabolic disease target. Xenon identified the drug target as part of its iron metabolism program (see Xenon news release dated December 19, 2001) and has now developed and formatted an assay for high throughput screening. Screening of compounds using this assay will be undertaken by Discovery Partners under the agreement. On September 27, 2001, Xenon Genetics and Discovery Partners announced their first drug discovery agreement for screening of another genetically derived metabolic target discovered by Xenon. Said Frank Holler, Chief Executive Officer of Xenon Genetics, "This is the third genetically derived drug target Xenon has taken into compound screening within the last 12 months and we expect to advance more targets into screening in the coming year. We are also delighted to advance our relationship with Discovery Partners, thereby building on the success of our earlier screening program with them." Said Michael Hayden, Chief Scientific Officer of Xenon Genetics, "Advancing our iron metabolism program into compound screening demonstrates once again Xenon's ability to identify clinically relevant genes through our comprehensive genetics approach, and then rapidly validate these genes as drug targets. This rapid validation of genetically derived targets is key to our competitive advantage as it significantly shortens the drug discovery timeline."<< snip DPII was supposed to have commercialized the high throughput screening technology licensed from Abbot by now. I have heard nada. Cheers, Tuck

To: tom pope who wrote (1000)	1/10/2002 1:49:58 PM
From: nigel bates	Read Replies (1) \| Respond to of 1784

Congratulations to Trickle to reaching 1000 posts (& I suppose to tom for snagging it <g>). Don't know if SMMX quite qualifies as Trickle, but thought this was interesting - Symyx Technologies Announces Discovery Tools Agreement with Lilly SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 7, 2002--Symyx Technologies, Inc. (Nasdaq:SMMX - news) announced today that it has entered into an agreement with Eli Lilly and Company (NYSE:LLY - news) which is aimed at enhancing the rapid discovery, identification and characterization of novel polymorphic forms of Lilly's drug candidates. Under the agreement, Lilly will purchase a Symyx® polymorph Discovery Tools® system and two Symyx solubility workflow systems, all of which Symyx intends to ship to Lilly during 2002. The polymorph system is a high throughput system in development that is designed to rapidly identify optimal crystalline salt and polymorphic form of drug candidates. The solubility workflow system is an integrated software and instrumentation system that is expected to enable high throughput automated testing of drug candidates for formulation and preformulation assessment. Selection of the correct form of the drug for clinical trials is an important part of drug development. Molecules often crystallize in more than one polymorphic form depending on the specific crystallization and purification conditions used. Each polymorph has a unique set of physiochemical properties such as melting point, solubility, stability, and bioavailability. Early selection of the crystalline polymorph with the best overall properties is critically important to pharmaceutical companies to avoid identifying a new, previously unidentified polymorph of a drug candidate later in the drug development process. This is the second agreement Symyx has completed in the field of pharmaceutical preformulation and formulation. The first was an agreement with Merck & Co., announced in June 2001. Under that agreement, Merck is providing funding for the development of Symyx' Discovery Tools polymorph system and will purchase the first commercial system upon completion and validation. Symyx intends to ship the Merck system in late 2002. ``We are very pleased to be working with Lilly, as we continue to demonstrate the value of our high throughput technologies in the drug development process,'' stated Steve Goldby, chairman and chief executive officer of Symyx Technologies. Symyx develops and applies high-speed combinatorial technologies to the discovery of materials for life science, chemical and electronics applications. Symyx provides research services to its partners through its Industry Collaborations business, seeks to license discovered materials through its Proprietary Materials programs, and offers selective access to its proprietary technologies, including instruments, software and intellectual property, through its Discovery Tools business. Approximately 25 leading life sciences, chemical and electronic companies are among Symyx' increasing base of worldwide partners and customers. Information about Symyx, including reports and other information filed by the Company with the Securities and Exchange Commission, is available on the worldwide web at www.symyx.com or by phoning 408/773-4095. ``Symyx'', the logo, ``Discovery Tools,'' and ``Library Studio'' are registered trademarks and servicemarks of Symyx Technologies, Inc. Other trademarks of Symyx Technologies, Inc. include ``Endeavor'' and ``Celero''...